Drug Details
PRM-151 is recombinant human pentraxin-2 (rhPTX-2), a novel antifibrotic agent with activity on monocyte differentiation, being studied for the treatment of IPF
Study Purpose
This Phase III Study will Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of PRM-151 Compared with Placebo in Participants with Idiopathic Pulmonary Fibrosis (IPF).
